Alumis

​​​​​​​Alumis cuts IPO size, but nets $250M for immune drug work
BioPharma Dive
Fri, 06/28/24 - 11:37 am
Alumis
IPOs
Alumis eyes IPO of over $300M to fund clinical-stage TYK2 pipeline
Fierce Biotech
Mon, 06/24/24 - 10:55 am
Alumis
IPOs
TYK2 inhibitors
ESK-001
Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu
BioPharma Dive
Mon, 06/10/24 - 11:17 am
Alumis
IPOs
funding
Bristol Myers Squibb
Sotyktu
psoriatic arthritis